(50 mg/kg twice daily SC or 100 mg/kg/day)
|
Inhibition of parasite phosphofructokinase metabolism
|
|
Local pain at site of injection, pancreatitis, nephrotoxicity
|
|
|
|
|
Impairment of signaling pathways and cell membrane synthesis
|
|
Anorexia, vomiting, diarrhea
|
|
|
|
|
Interference with mitochondrial pathway
|
|
Nephrotoxicity, ototoxicity
|
|
|
(10 mg/kg, PO, twice daily)
|
Interference with purine metabolism
|
|
Xanthinuria, urolithiasis, renal mineralization
|
|
|
(50 mg/kg,SC, twice daily or 100 mg/kg daily) +
allopurinol (10 mg/kg, PO, twice daily)
|
Inhibition of parasite phosphofructokinase metabolism and interference with purine metabolism
|
4 weeks (meglumine antimoniate) and 6-12 months (allopurinol)
|
Local pain at site of injection, pancreatitis, nephrotoxicity; xanthinuria, urolithiasis, renal mineralization
|
|
|
Miltefosine (2 mg/kg daily) +
allopurinol (10 mg/kg, PO, twice daily)
|
Impairment of signaling pathways and cell membrane synthesis and interference with purine metabolism
|
4 weeks (miltefosine) and 6-12 months (allopurinol)
|
Anorexia, vomiting, diarrhea, xanthinuria, urolithiasis, renal mineralization
|
|
|
Marbofloxacin (2 mg/kg daily)
|
|
|
|
|
|
Liposomal amphotericin B (3 mg/kg, IV, every 2 days)
|
Inhibition of cholesterol incorporation into cell membrane.
|
To total of 21 mg/kg over 2-3 weeks as tolerated
|
Diarrhea, vomiting, nephrotoxicity
|
|
|
